- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06293469
Couverture accélérée du lambeau en cas de traumatisme grave des membres inférieurs (FLAP ATTACK)
Couverture accélérée des lambeaux par rapport au calendrier standard dans le traitement des blessures musculo-squelettiques graves des membres inférieurs
The goal of this randomized controlled trial is to determine if accelerated flap coverage compared to standard flap coverage timing leads to improved infection-related complications in patients with open fractures and/or dislocations below the knee. Eligible patients will be randomized to receive either a flap within a goal of 72 hours of injury or standard of care flap timing for the institution. The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility).
This is the vanguard and international part of the FLAP ATTACK trial.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Infection following severe lower extremity musculoskeletal injuries is a challenging problem. Several factors hypothesized to influence infection have been explored and, in many cases, optimized or found not to be influential. A persistent area of uncertainty and variability is the timing of acute soft tissue coverage. In the United States, the mean time to coverage from injury is 10 days, and infection rates are 20-35%. In the United Kingdom, there are national guidelines to support coverage within 72 hours of injury, and infection rates are less than 10%. While the data to support early coverage is promising, the necessary evidence to make this significant change is lacking. To justify the mobilization of resources and expense required to shift practice, a definitive trial is needed. This trial seeks to fill this critical knowledge gap.
The primary objective of this trial is to determine if accelerated flap coverage (within 72 hours of injury) compared to standard flap coverage timing leads lower rates of infection and infection-related complications. The trial population includes patients 18 years and older with an acute open fracture and/or dislocation below the knee, with a diagnosed need for acute soft tissue coverage with a flap. Patients who undergo primary amputation prior to attempted flap coverage will be excluded. There will be 356 participants randomized in 1:1 ratio to receive either accelerated flap coverage (goal of flap within 72 hours from injury) or flap coverage at the time that reflects the standard of care at each institution. The timing of the trial interventions, other adjunctive treatments, the fracture fixation, and flap coverage procedures will be documented for both treatment groups. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. Participants will have follow-up at 6 weeks, 3 months, 6 months, and 12 months post-randomization.
The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility). The secondary outcomes will independently assess the individual components of the primary outcome at 6 and 12 months, the composite outcome at 12 months, and health-related quality of life and patient satisfaction over 6 and 12 months. An Adjudication Committee will review primary and secondary endpoints and a Data Safety Monitoring Committee (DSMC) will review all safety events.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Lily Mundy, MD
- Numéro de téléphone: 410-706-2492
- E-mail: LMundy3@jhu.edu
Lieux d'étude
-
-
Victoria
-
Melbourne, Victoria, Australie, 3004
- Recrutement
- The Alfred Hospital
-
Contact:
- Lipi Shukla, MBBS, PhD
-
Chercheur principal:
- Lipi Shukla, MBBS, PhD
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1N1
- Recrutement
- Vancouver General Hospital
-
Contact:
- David Stockton, MD
- Numéro de téléphone: 604-875-4111
- E-mail: david.stockton@vch.ca
-
-
New Brunswick
-
Saint John, New Brunswick, Canada, E2L 4L2
- Recrutement
- Saint John Regional Hospital
-
Contact:
- Alison Wong, MD
- Numéro de téléphone: 506-648-6000
- E-mail: alison.wong@dal.ca
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Recrutement
- Sunnybrook Health Sciences Centre
-
Contact:
- Jana Dengler
- Numéro de téléphone: 416-480-6100
- E-mail: jana.dengler@sunnybrook.ca
-
-
-
-
-
Barcelona, Espagne, 08035
- Recrutement
- Vall d'Hebron University Hospital
-
Contact:
- Jordi Tomás-Hernández, MD
-
Chercheur principal:
- Antonio Bulla, MD, PhD
-
Chercheur principal:
- Jordi Tomás-Hernández, MD
-
-
-
-
California
-
Sacramento, California, États-Unis, 95817
- Recrutement
- UC Davis Medical Center
-
Contact:
- Ara A Salibian, MD
-
Chercheur principal:
- Ara A Salibian, MD
-
Chercheur principal:
- Augustine M Saiz, MD
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Recrutement
- The Johns Hopkins Hospital
-
Contact:
- Lily R Mundy, MD
-
Chercheur principal:
- Lily R Mundy, MD
-
Baltimore, Maryland, États-Unis, 21224
- Recrutement
- John Hopkins Bayview Medical Center
-
Contact:
- Lily R Mundy, MD
-
Chercheur principal:
- Lily R Mundy, MD
-
Baltimore, Maryland, États-Unis, 21201
- Recrutement
- R Adams Cowley Shock Trauma Center
-
Contact:
- Mark J Gage, MD
-
Chercheur principal:
- Mark J Gage, MD
-
Largo, Maryland, États-Unis, 20774
- Recrutement
- University of Maryland Capital Region Medical Center
-
Contact:
- Todd Jaeblon, MD
-
Chercheur principal:
- Todd Jaeblon, MD
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Recrutement
- Oregon Health & Science University
-
Contact:
- Graham J DeKeyser, MD
-
Chercheur principal:
- Graham J DeKeyser, MD
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232
- Recrutement
- Vanderbilt University Medical Center
-
Contact:
- Lauren M Tatman, MD
-
Chercheur principal:
- Lauren M Tatman, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
The inclusion criteria are:
- Patients 18 years of age or older.
- Severe lower extremity open fracture and/or dislocation below the knee requiring an acute flap for management of the musculoskeletal injury.
- Will have all planned flap surgeries performed by a participating surgeon or delegate.
- Able to be randomized within 48 hours of injury.
The exclusion criteria are:
- Site is unable to implement the accelerated flap protocol due to local logistics.
- Primary amputation anticipated prior to attempted flap for management of the injury.
- Critical limb ischemia that requires re-vascularization for limb perfusion.
- Chronic or acute infection at or near the musculoskeletal injury site at the time of initial injury surgery.
- Burns at the musculoskeletal injury site.
- Incarceration.
- Expected injury survival of less than 12 months.
- Terminal illness with expected survival of less than 12 months.
- Currently enrolled in a trial that does not permit co-enrollment.
- Declined to provide informed consent.
- Unable to obtain informed consent due to language barriers.
- Unable to obtain informed consent because a legally authorized representative was unavailable.
- Anticipated problems, in the judgment of research personnel, with maintaining follow-up with the patient.
- Prior enrollment in the trial.
- Eligible patient or LAR was not approached within screening window (missed participant).
- Other reason to exclude the patient, as approved by the Principal Investigators.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Accelerated Flap Coverage
Accelerated flap surgery timing at a goal of within 72 hours from injury. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. |
Timing of the flap surgery is with a goal of 72 hours from injury |
|
Comparateur actif: Standard of Care Flap Timing
The flap surgery will be performed at the standard of care timing for the institution. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. |
Timing of the flap surgery is the standard of care flap timing for the participating institution. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Clinical status
Délai: 6 months
|
Clinical status is a hierarchical composite of the following outcomes:
|
6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mortality
Délai: 6 months and 12 months
|
All-cause mortality. Mortality will be time-to-event, with the assumption that earlier is worse than later. |
6 months and 12 months
|
|
Amputation
Délai: 6 months and 12 months
|
Amputation related to injury. Amputation will be time-to-event, with the assumption that earlier is worse than later. |
6 months and 12 months
|
|
Unplanned re-operation
Délai: 6 months and 12 months
|
Unplanned re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure). Re-operation for infection and major flap complication will account for more than one operation, assuming that more operations are worse. |
6 months and 12 months
|
|
Number of days in hospital
Délai: 6 months and 12 months
|
Days in an acute in-patient hospital (i.e., not rehab or nursing facility) |
6 months and 12 months
|
|
Patient-reported health status as assessed by the Euro-QoL (EQ-5D-5L)
Délai: 6 months and 12 months
|
Patient-reported health status as assessed by the EQ-5D-5L. The EQ-5D-5L is scored on a 0 to 100 mm scale. 0 mm represents "the worst health you can imagine to 100 mm which represents "the best health you can imagine". |
6 months and 12 months
|
|
Quality of life as assessed by the Limb-Q
Délai: 6 months and 12 months
|
Health-related quality of life and patient satisfaction measured with the Limb-Q. The Limb-Q is a set of independently functioning scales. All scales are scored 0-100 (higher = better). The Limb-Q Appearance, Physical, Symptoms, Financial Impact, Life Impact, and Psychological scales will be used. |
6 months and 12 months
|
|
Clinical Status
Délai: 12 months
|
Clinical status is a hierarchical composite of the following outcomes: 1. All-cause mortality 2. Amputation related to injury 3. Re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure) 4. Days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility) |
12 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Lily Mundy, MD, Johns Hopkins School of Medicine
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IRB00434587
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .